fashion -WSS

fashion

author：focus 2025-09-30 23:39:32 - browse：14832

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： AI models in health care face new federal disclosure requirements

WSS

FDA needs staff influx to meet gene therapy needs, Marks says

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Patients' immediate access to test results puts radiologists in a bind

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Was Amgen transparent enough on FDA's concern on cancer drug?

explore

fashion

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Radiology is caught between AI's potential and concern for patients

At least 13 dead in Texas as scorching temps continue

The future of health care in the House

United colonoscopy coverage change 'may cost lives,' doctors say

The future of health care in the House

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Patients' immediate access to test results puts radiologists in a bind

Sports medicine is finally prioritizing gender equality

Americans' trust in science, scientist continues decline: Report

hotspot

Why Charlie Gard's case is so disturbing to Americans

Colorectal cancer study finds potential in overlooked immune cell

Roche to buy Carmot Therapeutics, developer of obesity drugs

Physician executives need more than on

Sana to lay off nearly a third of staff, de

Liquid biopsy for lung cancer is launched by Delfi

hotspot

entertainment

knowledge

leisure time